Adia med leads charge to standardize umbilical cord stem cell use nationwide, prepares presentation for new head of dhhs and fda

Winter park, florida--(newsfile corp. - march 20, 2025) - adia med, a division of adia nutrition inc. (otc pink: adia), is driving a transformative effort to standardize umbilical cord stem cell use across the united states, prioritizing quality, safety, and accountability. this initiative sets rigorous best practices, mandates third-party verification, and ensures homologous applications, aiming to redefine excellence in regenerative medicine.
STEM Ratings Summary
STEM Quant Ranking